A5032713965- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Childhood Cancer Survivors' Quality of Life
- Chronic Lymphocytic Leukemia Research
- Genomic variations and chromosomal abnormalities
- Lymphoma Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Cancer Genomics and Diagnostics
- Hematopoietic Stem Cell Transplantation
- Adolescent and Pediatric Healthcare
- CAR-T cell therapy research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Renal and related cancers
- Retinoids in leukemia and cellular processes
- Eosinophilic Disorders and Syndromes
- Hemoglobinopathies and Related Disorders
- Cancer-related gene regulation
- Lung Cancer Research Studies
- Drug Transport and Resistance Mechanisms
- Glutathione Transferases and Polymorphisms
- Advanced biosensing and bioanalysis techniques
- DNA and Nucleic Acid Chemistry
- Prenatal Screening and Diagnostics
- RNA modifications and cancer
Newcastle University
2016-2025
Blood Cancer UK
2003-2022
University of Newcastle Australia
2010-2022
Illumina (United States)
2022
Bridge University
2022
Illumina (United Kingdom)
2022
Northumbria University
2022
Clinical Research Institute
2021-2022
University College London
1994-2021
Bristol Royal Hospital for Children
2021
Karyotype is an independent indicator of prognosis in acute myeloid leukemia (AML) that widely applied to risk-adapted therapy. Because AML rare children, the true prognostic significance individual chromosomal abnormalities this age group remains unclear.This cytogenetic study 729 childhood patients classified them into 22 subgroups and evaluated their incidence risk.Rearrangements 11q23 were most frequent abnormality found approximately 16% patients, with 50% these infants. The outcome for...
Abstract Chromosomal rearrangements are initiating events in acute lymphoblastic leukaemia (ALL). Here using RNA sequencing of 560 ALL cases, we identify between MEF2D (myocyte enhancer factor 2D) and five genes ( BCL9 , CSF1R DAZAP1 HNRNPUL1 SS18 ) 22 B progenitor (B-ALL) cases with a distinct gene expression profile, the most common which is MEF2D-BCL9 . Examination an extended cohort 1,164 B-ALL identified 30 rearrangements, include additional fusion partner, FOXJ2 ; thus, MEF2D-...
Summary We investigated the outcome for children and young people with Early T‐precursor acute lymphoblastic leukaemia (ETP‐ALL), a recently described poor prognosis sub‐group of T‐ALL, treated on contemporary protocol, UKALL 2003. After median follow‐up 4 years 10 months, ETP sub‐group, representing 16% T‐ALL patients, had non‐significantly inferior 5‐year event‐free survival (76·7% vs. 84·6%, P = 0·2) overall (82·4% 90·9%, 0·1), higher relapse rate (18·6% 9·6%, 0·1) compared to typical...
Abstract Childhood B-cell acute lymphoblastic leukaemia (B-ALL) is characterised by recurrent genetic abnormalities that drive risk-directed treatment strategies. Using current techniques, accurate detection of such aberrations can be challenging, due to the rapidly expanding list key abnormalities. Whole genome sequencing (WGS) has potential improve testing, but requires comprehensive validation. We performed WGS on 210 childhood B-ALL samples annotated with clinical and data. devised a...
Glutathione S -transferases (GSTs) detoxify potentially mutagenic and toxic DNA-reactive electrophiles, including metabolites of several chemotherapeutic agents, some which are suspected human carcinogens. Functional polymorphisms exist in at least three genes that encode GSTs, GSTM1, GSTT1, GSTP1. We hypothesize, therefore, GSTs alter susceptibility to chemotherapy-induced carcinogenesis, specifically therapy-related acute myeloid leukemia (t-AML), a devastating complication long-term...
This analysis, of 2483 patients with acute myeloid leukaemia (AML) aged 60+ years entered into two UK trials, was performed to determine the baseline parameters related survival and develop a risk index. The Medical Research Council (MRC) AML11 trial (n = 1071) used index; this validated using data from Leukaemia fund (LRF) AML14 on 1137 intensively (AML14I) 275 non-intensively (AML14NI) treated patients. In AML11, cytogenetic group, age, white blood count, performance status type AML (de...